best peptides FAQ

Slow the titration schedule to 20–24 weeks instead of the standard 12-week ramp, or split your weekly dose into two smaller injections spaced 3–4 days apart. Nausea peaks 24–48 hours post-injection when plasma concentration is highest. Dividing the dose flattens the concentration curve and reduces GI side effects by 30–40%. Alternatively, start with mazdutide instead of survodutide: GIP agonism causes less gastric slowing than glucagon activation, making it better tolerated in patients with pre-existing gastroparesis.

Peptides that enhance angiogenesis. Specifically BPC-157. May offer the most benefit in avascular or hypovascular fracture sites where blood supply limits healing. The navicular bone and proximal fifth metatarsal are notorious for non-union precisely because capillary density is insufficient to deliver osteoblasts and mineral precursors. VEGF upregulation creates new vessel networks, theoretically improving nutrient delivery. However, no published research has compared peptide efficacy across different fracture sites or bone vascularity levels. This remains an extrapolation from general angiogenesis data.

Color change in copper peptide formulations indicates oxidation. The copper ion has interacted with air or light and the peptide has partially degraded. Effectiveness drops by approximately 30–50% once discoloration is visible. Store unopened peptide serums in a cool, dark location and refrigerate after opening. Most copper peptide formulations remain stable for 3–4 months after opening if refrigerated; palmitoyl peptides last 6–8 months. If your serum has changed color, replace it. Using oxidised peptides is not harmful, but you are applying an inactive compound.

Growth hormone secretagogues preserve muscle mass during deficit but don't independently create fat loss. If you're in a verified caloric deficit (tracked intake below TDEE for 4+ weeks) without weight change, the issue is likely metabolic adaptation. Your body has downregulated NEAT and thermogenesis to match reduced intake. Adding a GH secretagogue like MK-677 prevents further muscle loss, which preserves basal metabolic rate, but you'll still need to either deepen the deficit or introduce a compound like semaglutide that directly reduces hunger signaling. The secretagogue buys time. It stops the metabolic slowdown from getting worse. But doesn't reverse a plateau on its own.

Increase injection frequency from twice weekly to three times weekly rather than raising dose per injection. GH secretagogues work through pulsatile release. More frequent pulses sustain elevated HSL activity better than higher single doses. Simultaneously, assess whether your caloric deficit has narrowed due to metabolic adaptation (TDEE drops 10–15% after 6–8 weeks of restriction). Recalculate maintenance calories and restore a 300–500 calorie deficit. Peptides accelerate fat oxidation, but they cannot override thermodynamic reality. If energy balance is neutral, fat loss stops regardless of peptide protocol.

Discard it. A peptide left at room temperature (20–25°C) for more than 6–8 hours has undergone partial denaturation. The protein's tertiary structure has been compromised. You can't tell by looking at it, and attempting to use it risks injecting an inactive or partially active compound. The cost of replacing one vial is far lower than the wasted time and effort of continuing a protocol with degraded material.

Reassess protein intake first. IGF-1 elevation without leucine threshold saturation (3–4 grams per meal) fails to activate mTOR sufficiently for hypertrophy. Research shows that even with elevated growth hormone, muscle protein synthesis rates remain unchanged if amino acid availability is suboptimal. Verify you're consuming 1.6–2.2 grams protein per kilogram bodyweight daily, distributed across 4–5 meals. Second checkpoint: confirm your peptide source purity through third-party testing. Underdosed or degraded peptides won't elevate IGF-1 meaningfully, and plasma IGF-1 testing is the only definitive verification method.

Apply KPV topically (2–5mg/mL formulation) twice daily to the affected area immediately at flare onset. Research shows maximal efficacy when initiated within 24 hours of symptom appearance, as NF-κB activation peaks during the first 48 hours of inflammation. Continue application for 14–21 days even after visible resolution. Stopping prematurely allows subclinical inflammation to rebound within 7–10 days.

First, verify your reconstitution and storage methods. Most 'non-responders' had preparation errors. Second, confirm baseline testosterone and IGF-1 levels with bloodwork. If your IGF-1 hasn't increased, the peptide isn't working (whether due to product quality, dosing error, or individual non-response). Third, assess lifestyle factors: inadequate sleep, chronic caloric deficit, or overtraining all suppress the HPG axis and can blunt peptide effects. If all three check out and you're still a non-responder, consider switching peptides or consulting an endocrinologist to rule out primary hypogonadism.

No interference occurs when used at different times of day. Apply peptide serums in the morning after cleansing, then apply retinoid at night. The mechanisms do not compete. Retinoids increase cell turnover and upregulate retinoic acid receptors in keratinocytes, while peptides activate fibroblast signaling pathways in the dermis. A 2021 study in Clinical, Cosmetic and Investigational Dermatology found that combined retinoid-peptide regimens produced 47% greater improvement in acne scar appearance than retinoid alone after 16 weeks. The retinoid accelerates surface exfoliation and enhances peptide penetration by thinning the stratum corneum, while the peptide addresses the underlying collagen deficit that retinoids cannot directly affect.

NSAIDs (ibuprofen, naproxen) inhibit cyclooxygenase-2 (COX-2), which reduces prostaglandin synthesis. Prostaglandins signal osteoblast activity during the inflammatory phase, so chronic NSAID use during weeks 0–3 can delay fracture healing by 20–30%. Corticosteroids suppress the entire inflammatory cascade, which is even more problematic. If pain management requires NSAIDs, limit use to the first 48–72 hours and switch to acetaminophen thereafter. Peptides can't fully compensate for anti-inflammatory drug interference, but they may mitigate some of the delay.

Increased shedding 4–8 weeks into a peptide regimen often reflects follicles transitioning from prolonged telogen into anagen. The old telogen hair must shed before the new anagen hair emerges. This is distinct from the initial stress-induced shedding, which occurs 8–12 weeks after cortisol spikes. If shedding worsens beyond week 8 or you notice scalp inflammation (redness, itching, flaking), discontinue and assess for allergic reaction or contamination. Research-grade peptides from facilities like Real Peptides undergo purity verification via HPLC and mass spectrometry. Contaminated peptides from unverified suppliers can trigger immune responses that worsen hair loss rather than improve it.

MK-677 increases aldosterone secretion in 30–40% of users, causing extracellular water retention that shows up as scale weight but not intramuscular hypertrophy. The visual difference: subcutaneous puffiness in the face and ankles versus muscle fullness in trained muscle groups. Measure body composition through DEXA or bioelectrical impedance weekly. If lean body mass is increasing alongside total body water, the protocol is working. If only water weight rises without corresponding strength or circumference gains, reduce MK-677 dose to 12.5 mg daily or switch to a pulsatile secretagogue like CJC-1295 that doesn't elevate aldosterone.

No research has directly tested peptide combinations for bone healing, but mechanistic logic suggests potential synergy: BPC-157 for angiogenesis and early callus formation, TB-500 for anti-fibrotic effects during repair, and GHK-Cu for collagen maturation during remodeling. The risk is overlapping pathways that produce diminishing returns or unanticipated receptor saturation. Animal studies showing benefit used single peptides, meaning combination protocols are entirely speculative. Our experience with researchers in this space suggests sequencing peptides by healing phase rather than concurrent administration. BPC-157 weeks 1–4, TB-500 weeks 3–8, GHK-Cu weeks 6–12.

Tesofensine produces weight loss through dopamine/norepinephrine reuptake inhibition without affecting gastric motility, eliminating the nausea and vomiting common with GLP-1 therapy. The trade-off is CNS side effects. Dry mouth, insomnia, occasional anxiety. Rather than gastrointestinal distress. Clinical trials showed 10.6% mean body weight reduction at 0.5mg daily over 24 weeks, which is lower than tirzepatide but achieved without slowing digestion. For individuals with gastroparesis, GERD, or other GI conditions where delayed gastric emptying would worsen symptoms, Tesofensine represents the most evidence-backed alternative mechanism.

Isolate variables through controlled introduction periods. Start with a single secretagogue (CJC-1295 + Ipamorelin or MK-677 alone) for 4–6 weeks, tracking strength, body composition, and recovery metrics weekly. Add adjunct peptides (BPC-157, TB-500, Thymalin) one at a time with 2–3 week observation windows between additions. Most lean mass response comes from the primary GH secretagogue. Ancillary peptides improve recovery and injury resilience but don't independently drive hypertrophy. If you can't attribute specific changes to specific compounds, you're likely wasting money on redundant mechanisms.

Administer peptides only after initial hematoma formation stabilises. Typically 48–72 hours post-injury. The acute inflammatory phase requires controlled cytokine expression (IL-1β, TNF-α, IL-6) to initiate the repair cascade, and premature anti-inflammatory intervention can delay osteoblast recruitment. BPC-157 has shown pro-angiogenic effects without suppressing early inflammation, making it theoretically safer during this window than NSAIDs, which directly inhibit COX enzymes critical to prostaglandin-mediated bone healing. TB-500's anti-inflammatory properties suggest delaying administration until week 2, when excessive inflammation becomes counterproductive.

Testosterone optimises DHT signalling to androgen receptors, but it doesn't directly raise IGF-1 in dermal tissue the way GH-releasing peptides do. Men on TRT with adequate DHT conversion but suboptimal GH secretion may still see density improvements from adding CJC-1295/Ipamorelin or MK-677. The pathways are complementary, not redundant.

Metabolic adaptation is the likely cause. Your body downregulates NEAT (non-exercise activity thermogenesis) by 200–400 calories/day and reduces thyroid hormone conversion (T4 to T3) in response to sustained deficit. Solutions: implement a 10–14 day maintenance phase at estimated TDEE to restore leptin and thyroid function, then resume deficit. Alternatively, add Lipo-C (methionine, inositol, choline) to support hepatic fat metabolism and methylation pathways that regulate energy expenditure.

Administer BPC-157 at 500mcg twice daily, injected subcutaneously near the medial elbow. Pair with TB-500 at 2.5mg twice in the first week to reduce inflammation and promote tissue migration to the injury site. This won't fully repair a Grade II tear in two weeks—that requires 6–8 weeks under normal circumstances—but it accelerates the initial inflammatory phase and early collagen deposition enough that pain and grip strength may improve sufficiently for competition. You're managing damage, not reversing it. Post-fight, continue both peptides for another 4–6 weeks to complete structural repair.